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Abstract
Diets rich in flavonoids have been reported to have beneficial effects in the primary preven-
tion of cardiovascular events. There are limited data, however, on the cardiovascular bene-
fits of purified flavonoids. The aim of this systematic review and meta-analysis was to
examine the reported effects of isolated flavonoids on aortic atherosclerosis in a mouse
model. Medline, Pubmed, Science direct and Web of Science were searched to identify
studies which examined the effect of isolated flavonoids on aortic atherosclerosis in apolipo-
protein E deficient mice. A meta-analysis was performed to determine the overall effect of
the flavonoids, and sub-analyses were performed to compare the effects of the flavonols
and flavan-3-ols. Eleven studies, which examined a total of 208 mice receiving a flavonoid
and 126 control mice, were included. Overall the flavonoids significantly reduced aortic ath-
erosclerosis (SMD 1.10, 95% CI 0.69, 1.51). Of the 18 flavonoid interventions examined 12
were flavonols and 3 were flavan-3-ols. Sub-analyses suggested that the flavonols (SMD
1.31, 95% CI 0.66, 1.91) but not the flavan-3-ols (SMD 0.33, 95% CI -0.19, 0.85) signifi-
cantly decreased atherosclerosis area. Of the eleven studies, only one examined histologi-
cal markers of atherosclerosis plaque stability. Most studies did not report blinding of
outcome assessors or reproducibility of the primary outcome, and did not justify the sample
size used and flavonoid dose administered. Based on the included studies, the flavonols
appear to be the most effective flavonoids for reducing aortic atherosclerotic lesion area in
apolipoprotein E deficient mice.
Introduction
Atherosclerosis and associated thrombosis are the main underlying cause of stroke, myocardial
infarction and peripheral artery disease which, collectively, are the leading cause of death glob-
ally [1]. Much of the focus on the primary and secondary prevention of cardiovascular disease
over the last few decades has been on drugs to manage cardiovascular risk factors such as
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statins, blood pressure lowering medications and anti-platelet agents [2–4]. Diet has been
linked to the development and complications of cardiovascular disease for centuries however
it is only more recently that trials demonstrating the benefits of dietary interventions in
humans have been completed [5–7]. A recent multicentre randomized controlled trial, which
included 7447 participants, reported that the Mediterranean diet with either extra virgin olive
oil or nut supplementation reduced the incidence of cardiovascular end points by 30%, com-
pared to control subjects educated on a low fat diet [8]. The beneficial effects of extra virgin
olive oil and nuts have been linked to their high phenolic content [9, 10], and reductions in
blood pressure and low density lipoprotein (LDL) oxidation have been reported for other
foods high in phenols including dark chocolate, green tea, apples, tomatoes, kale, lettuce and
onions [11–13].
A subclass of phenols, known as the flavonoids, have been of particular interest in recent
research for their potent anti-oxidant and anti-atherosclerosis effects [14]. The most studied
flavonoids are the flavan-3-ols, the flavonols, and the flavonol glycosides (e.g. enzymatically
modified isoquercitrin; EMIQ) (Fig 1) [15, 16]. However, the impact of consuming purified
flavonoids on cardiovascular events have not been examined in human clinical trials.
Apolipoprotein E deficient (ApoE-/-) mice have been used to assess the effect of flavonoids
on atherosclerosis, however the overall effect of the flavonoids, and the effect of individual clas-
ses of flavonoids on the severity of atherosclerosis remain unclear. The ApoE-/- mouse model
is particularly useful for studying atherosclerosis due to its quick and predictable development
of atherosclerosis [18, 19]. Furthermore, the model responds to lipid lowering interventions
which have been shown to reduce complications of atherosclerosis in humans [18, 20, 21]. The
aim of this systematic review and meta-analysis was to examine the effect of purified flavo-
noids on the severity of aortic atherosclerosis in ApoE-/- mice.
Materials and methods
Search strategy, inclusion and exclusion criteria
This review was prepared according to the 2009 Preferred Reporting Items of Systematic
Reviews and Meta-Analyses (PRISMA) statement. Literature searches were conducted to
identify pre-clinical studies testing the effects of flavonoids on atherosclerosis lesion area in
ApoE-/- mice. Medline, Pubmed, Science direct and Web of Science were searched between
16th March 2016 and 27th May 2017. Science direct searches were filtered to include only jour-
nal articles. The full search strategy included the terms ("Apolipoprotein E" OR ApoE) AND
Fig 1. Properties of the major flavonoid classes (examples in brackets) used in atherosclerosis research in apolipoprotein E mice.
Catechin and epicatechin are flavan-3-ols; Quercetin, Kaempferol and Isorhamnetin are flavonols; and EMIQ and myricitrin are flavonol
glycosides. EMIQ, Enzymatically modified isoquercitrin; R, glucose chain (n = 3–9). Adapted from de Pascual-Teresa, Moreno [17].
https://doi.org/10.1371/journal.pone.0181832.g001
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(Mice OR Mouse) AND (Phenol OR Flavonoid OR Quercetin OR Catechin OR Glabridin
OR Kaempferol OR Epicatechin OR Baicalin OR Isorhamnetin) utilising both medical subject
headings (MeSH) and keyword searches. Resulting titles and abstracts from all years were
screened for relevance and all potentially eligible abstracts were assessed in full text by one
reviewer (JP). Reference lists of included studies were also screened for relevant articles. Con-
trolled studies which used purified flavonoids, or flavonoids with glucoside moieties such as
isoquercitrin, in an ApoE-/- mouse model were included. Of these, only studies which included
atherosclerosis lesion area as an outcome measure were included. Studies which did not report
atherosclerosis lesion area as a percentage or as lesion area out of total area measured were
excluded. Included studies were restricted to those published in English. Reviews, editorials,
books, letters, case reports, and clinical trials were excluded. Studies where sample size could
not be determined were excluded.
Data extraction and quality assessment tool
Full text articles eligible for data extraction were independently assessed by three authors (JP,
SMK and SMO) and results were later discussed in a consensus meeting. The data extracted
included mouse age, sex and diet, flavonoid purity and dose, duration of treatment, control
and treatment group sample sizes, location of atherosclerosis area assessed, stain used for
lesion assessment, lesion area as a percentage of total area, plasma triglyceride (TG), LDL cho-
lesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and
measures of LDL-oxidation and reactive oxygen species. Data were extrapolated from figures
in 10 of the studies using Adobe Photoshop CS6. In cases of missing data, corresponding
authors were contacted. Authors of seven papers were contacted [22–28], and two responded
[25, 27]. Study quality was assessed using a quality assessment tool adapted from a previous
preclinical systematic review (S1 Table) [29]. Questions focused on the reporting of study
design, mouse age and sex, diet, housing conditions, method of group allocation, ethics
approval, justification of sample sizes, justification of flavonoid dose, flavonoid purification
processes, methods of lesion area analysis and blinding procedures for outcome assessments.
Each question was assessed as a yes or no answer and the number of yes answers reported as a
percentage out of 17 questions, or out of 15 questions for studies that did not measure plasma
lipids. These percentage scores were used as an indication of overall study quality. Studies
were rated as poor (<50%), moderate (51–75%), good (76–90%), or excellent quality (91–
100%).
Statistical analysis
A meta-analysis was used to assess the overall effects of the administration of purified flavo-
noids on atherosclerosis lesion area in ApoE-/- mice. In four studies [30–33], the same control
group was used to compare multiple flavonoids or flavonoid doses. In these instances, the
number of control animals was divided by the number of comparator groups to prevent an
artificial increase in sample size in the meta-analysis. Sub-analyses were performed to test the
overall effect of the flavonols and flavan-3-ols on atherosclerosis lesion area.
Heterogeneity in the data was expected due to the use of multiple flavonoids, at different
doses with different durations of treatment, and therefore random effects models were used.
Data were expressed as standardised mean difference with 95% confidence intervals. Sensitiv-
ity analyses were performed using the leave one out approach to test the effect of each study on
the standard mean difference. I2 values were used to assess heterogeneity between studies. Het-
erogeneity above 30% was considered moderate, and heterogeneity above 50% was considered
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substantial. Funnel plots were used to test for publication bias. Statistical analyses were per-
formed using RevMan 5.3, and tests were considered significant when P values were<0.05.
Results
Study selection
Database searches identified a total of 1192 studies, of which 224 articles were duplicates (Fig
2). The titles and abstracts of the remaining 968 articles were screened and 942 were excluded.
Fig 2. Preferred Reporting Items of Systematic Review and Meta-analyses (PRISMA) flow diagram. A total of
1192 articles were identified from Science direct, Web of Science, Pubmed and Medline. Of these, 26 full-text articles
were assessed for eligibility and 11 articles were included in the review. Eight studies were excluded as they did not
measure atherosclerosis lesion area. One study was excluded as it administered a crude extract. Three studies were
excluded because sample sizes could not be retrieved and three studies were excluded because of insufficient data
for lesion area comparison. From: Mohar D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med 6(7): e1000097.
doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.
https://doi.org/10.1371/journal.pone.0181832.g002
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26 full text articles were assessed. Eight of these studies were excluded because atherosclerosis
lesion area was not reported and one study was excluded because a crude extract rather than
a purified flavonoid was administered. After contacting corresponding authors, a further
three studies were excluded because sample sizes for lesion area measurements could not be
obtained [22, 23, 27], and three studies were excluded after no reply from authors because total
area of the aorta measured was not reported [24, 28, 34]. In total, eleven studies were included
in the current systematic review and meta-analysis.
Study characteristics
The characteristics of the eleven included studies are shown in Table 1. Mice from all included
studies were male, except for one study in which the sex was not reported [30]. Mice received
a standard chow diet in three studies [25, 30, 32]; a high fat diet in seven studies containing
either 20% fat and 0.3% cholesterol [35–37], 21% fat and 1.25% cholesterol [33], 47% carbohy-
drates, 21% fat and 20% protein [26], or 1.25% cholesterol and 10% coconut oil [38, 39]; and
the American Institute of Nutrition (AIN) 93 diet, containing 4% fat, 73% carbohydrates, and
14% protein, in one study [31]. The age of the mice when flavonoid administration was initi-
ated was four weeks in one study [30], six weeks in seven studies [25, 26, 31, 33, 35–37], eight
weeks in one study [39], nine weeks in one study [38], and 15 weeks in one study [32]. Six
studies administered the flavonoids via the intragastric route [32, 35–39], two studies adminis-
tered the flavonoids by adding it to the drinking water [25, 30], and three studies administered
the flavonoids by adding to the chow [26, 31, 33].
The eleven included studies collectively measured the effects of nine unique flavonoids, at
multiple doses in a total of 18 comparisons, based on the outcome of atherosclerosis lesion
area. Quercetin was administered at 25, 50 and 100mg/kg/d for 24 weeks [33], 64mg/kg/d for
Table 1. Characteristics of studies included in this meta-analysis.
Study Flavonoid Purity Mouse Age
(weeks)
Mouse
Sex
Diet Study length
(weeks)
Dose (mg/
kg/d)
Route Lesion area
measured
Staining Analysis
[38] Baicalin 98% 9 Male HCD 12 100 IG Aortic root Oil red O Cross sectional
[39] Baicalin 98% 8 Male HFD 12 100 IG Aortic root Oil red O Cross sectional
[30] Catechin ? 4 ? SCD 6 ~1.6 Water Aortic arch Osmium
tetroxide
Cross sectional
[31] Epicatechin 98% 6 Male AIN-
93M
26 64 Chow Aortic Sinus,
Thoracic aorta
Sudan IV Cross sectional
[25] Glabridin 98% 6 Male SCD 6 ~0.6 Water Aortic valves Osmium Cross sectional
[26] EMIQ ? 6 Male HFD 14 ~30 Chow Aortic sinus Oil red O Cross sectional
[35] Isorhamnetin 98% 6 Male HFD 8 20 IG Aortic valves Oil red O Cross sectional
[32] Kaempferol 98% 15 Male SCD 4 50 or 100 IG Aortic root to Iliac
branches
Sudan IV En face
(longitudinal)
[37] Myricitrin 98% 6 Male HFD 8 50 IG Aortic root Oil red O Cross sectional
[36] Myricitrin 98% 6 Male HFD 6 50 IG Aortic root Oil red O Cross sectional
[30] Quercetin ? 4 ? SCD 6 ~1.6 Water Aortic arch Osmium Cross sectional
[31] Quercetin 98% 6 Male AIN-
93M
26 64 Chow Aortic Sinus,
Thoracic aorta
Sudan IV Cross sectional
[33] Quercetin 98% 6 Male HFD 24 25–100 Chow Aortic Sinus H&E Cross sectional
~ indicates dose was calculated based on average body weights and food consumption reported in previous ApoE-/- mouse studies. AIN, American institute
of Nutrition; EMIQ, enzymatically modified isoquercitrin; HCD, high-cholesterol diet; HFD, high-fat diet; IG, Intragastric; M, maintenance; SCD, standard
chow diet;
?
, unknown; H&E, hematoxylin and eosin.
https://doi.org/10.1371/journal.pone.0181832.t001
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26 weeks [31] and 1.6mg/kg/d for six weeks [30]. Myricitrin was used in two studies at 50mg/
kg/d for six weeks [37] and eight weeks [36]. Baicalin was administered at 100mg/kg/d for 12
weeks in two studies [38, 39]. Catechin was administered at 1.6mg/kg/d for six weeks [30]. Epi-
catechin was administered at 64mg/kg/d for 26 weeks [31]. Glabridin was given at 0.6mg/kg/d
for six weeks [25]. Isorhamnetin was administered at 20mg/kg/d for 8 weeks [35]. Kaempferol
was given at 50 and 100mg/kg/d for 4 weeks [32]. EMIQ was administered at 30mg/kg/d for
14 weeks [26]. Three studies did not report dose per kilogram and gave no body weight mea-
surements [25, 26, 30], therefore we calculated an estimated dose assuming an average mouse
weight of 30g per mouse [40] and an average food intake of 3.45g/d [41]. The purity of individ-
ual flavonoids was >98% in nine studies, as measured through high performance liquid chro-
matography [25, 31–33, 35–39]. The purification procedure was described but purity was not
stated in one study [26], and no flavonoid source or purification procedure was given for one
study [30].
Atherosclerosis lesion area
Ten studies measured cross sectional aortic lesion area in mice receiving flavonoids and con-
trols [25, 26, 30, 31, 33, 35–39]. Of these, nine of the studies measured aortic lesion area at the
level of the aortic root, sinus or valves [25, 26, 31, 33, 35–39], and one study also measured
lesion area within the thoracic aorta [31]. One study measured aortic lesion area only within
the aortic arch [30]. One study measured longitudinal aortic lesion area from the aortic root to
the iliac branches (Table 1) [32]. All studies reported that the administered flavonoid signifi-
cantly reduced atherosclerosis lesion area compared with control mice, except one study test-
ing epicatechin where no significant difference was reported (Table 2) [31].
Table 2. Effect of different flavonoids on atherosclerosis lesion area in ApoE-/- mice and key aspects of the methods of the included studies.
Study Flavonoid (Dose, mg/kg/d) Lesion area decrease (%) P< Sample
Size
Blinded Repeated measures Sample size justified Dose justified
C E
[38] Baicalin (100) 9.40 ± 5.70 0.05 10 10 N N N N
[39] Baicalin (100) 19.38 ± 3.26 0.01 5 5 N N N N
[30] Catechin (1.6) 2.09 ± 1.51 0.01 20 19 Y N N N
[31] Epicatechin (64) 5.31 ± 6.34 NS 20 19 N N Y Y
[31] Epicatechin (64) 5.43 ± 8.23 NS 20 19 N N Y Y
[25] Glabridin (0.6) 30.55 ± 7.70 0.01 14 14 N N N N
[26] EMIQ (30) 7.5 ± 4.30 0.01 8 7 N N N N
[35] Isorhamnetin (20) 19.21 ± 4.75 0.01 10 10 N N N N
[32] Kaempferol (50) 4.85 ± 1.14 0.05 10 10 N N N N
[32] Kaempferol (100) 8.84 ± 1.01 0.01 10 10 N N N N
[37] Myricitrin (50) 3.96 ± 5.01 0.05 10 10 N N N N
[36] Myricitrin (50) 8.11 ± 6.11 0.01 10 10 N N N N
[30] Quercetin (1.6) 2.44 ± 1.53 0.01 20 20 Y N N N
[31] Quercetin (64) 28.5 ± 4.63 0.05 20 18 N N Y Y
[31] Quercetin (64) 18.57 ± 8.27 0.05 20 18 N N Y Y
[33] Quercetin (25) 2.09 ± 1.93 NS 3 3 N N N Y
[33] Quercetin (50) 5.77 ± 1.94 NS 3 3 N N N Y
[33] Quercetin (100) 12.21 ± 1.95 0.05 3 3 N N N Y
NS, not significant; C, control; E, experimental group receiving flavonoid; Y, yes; N, no.
https://doi.org/10.1371/journal.pone.0181832.t002
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Plasma lipids
Eight studies measured plasma [25, 26, 31, 35, 38] or serum [36, 37, 39] TC, six studies mea-
sured plasma [26, 35, 37] or serum TG [36, 37, 39], six studies measured plasma [30, 35, 38] or
serum [36, 37, 39] LDL-C, and seven studies measured plasma [26, 30, 35, 38] or serum [36,
37, 39] HDL-C. In all studies, flavonoids were reported to have no significant effect on plasma
or serum TC, TG, LDL-C or HDL-C.
Oxidative stress
Three of the included studies measured the effects of flavonoids on indicators of oxidative
stress in mouse aortic tissue, including reactive oxygen species [32], oxysterols [25], and F2
isoprostanes [31]. One study measured the effect of flavonoids on serum oxidised LDL [37].
One study investigated the effects of flavonoids on susceptibility of mouse LDL to oxidation ex
vivo [30], and two studies measured oxidation in cultured cells [33, 36], with one also testing
NADPH oxidase activity [33]. One study investigated human LDL oxidation in the presence of
flavonoids ex vivo [25]. Quercetin [30] and glabridin [25] were reported to reduce LDL-oxida-
tion ex vivo, while catechin was not [30]. Myricitrin was reported to significantly reduce
serum LDL-oxidation in ApoE-/- mice [37]. Kaempferol was reported to reduce aortic reactive
oxygen species [32], and epicatechin and quercetin were reported to reduce plasma superoxide
concentrations [31].
Quality assessment of included studies
The mean quality assessment score for all eleven studies was 59% (moderate quality), with the
highest score being 76% (good quality) [31] and the lowest scoring being 20% (poor quality)
[25] (S1 Table). All studies failed to report intra- and inter-observer repeatability testing and
blinding of the outcome assessor during lesion area analyses. All studies failed to justify the
sample size and dose of flavonoids used, with the exception of one study [31]. Only one study
measured the concentration of the ingested flavonoid in the plasma of mice [30]. Body weights
were measured at the start and finish of the experiments in five studies [26, 31, 33, 36, 37]. Of
the eleven studies, three did not confirm that study conditions were identical between the con-
trol and treatment groups [25, 30, 37]. Ethics approval statements were missing from three
studies [25, 39, 42]. Two studies neglected to report the sex of the mice [25, 30], however email
correspondence confirmed the sex, starting age and diet in one of these studies [25]. One
study failed to report that animals were randomly allocated to control or intervention groups
[25]. One study did not report the purity of the flavonoid or the process of extraction [30]. All
eight studies which measured plasma lipids reported the source of assay reagents and equip-
ment used, however reproducibility testing for plasma lipid analyses was reported for only one
study [35].
Meta-analysis, sensitivity analyses and funnel plots
Eleven studies, including a total of 18 comparisons, tested the effects of flavonoids on aortic
atherosclerosis lesion area. A total of 208 flavonoid administered and 126 vehicle control
ApoE-/- mice were included in the overall meta-analysis (Fig 3). The overall effect of the flavo-
noids was to significantly lower atherosclerosis lesion area compared with controls (SMD 1.10,
95% CI 0.69, 1.51), however there was substantial heterogeneity between the studies (I2 =
56%). Sub-group analyses were performed to compare the effects of the flavonols and flavan-
3-ols on atherosclerosis lesion area. Administration of flavonols, including flavonol glycosides,
led to a significant decrease in atherosclerosis lesion area (SMD 1.31, 95% CI 0.74, 1.87) in a
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total of 122 experimental mice (77 control were included). The flavan-3-ols did not signifi-
cantly reduce atherosclerotic lesion area (SMD 0.33, 95% CI -0.19, 0.85), based on data from a
total of 57 experimental and 20 control mice.
Sensitivity analyses using the leave one out approach showed that all studies contributed to
the findings of the meta-analysis and the removal of individual studies did not change the
overall findings (S2 Table). Funnel plots suggested evidence of publication bias (S1 Fig).
Discussion
The main finding of this meta-analysis was that aortic atherosclerosis lesion area was signifi-
cantly lower after administration of flavonoids compared with controls in ApoE-/- mice. Find-
ings were generally consistent between studies however differences were seen in studies using
flavonols compared with the flavan-3-ols. There was a high degree of heterogeneity between
studies in terms of the flavonoid examined, starting age, the dose and diet administered, the
duration of treatment and area of the aorta which lesion area was measured. Mice in two stud-
ies were administered standard mouse chow with experimental end points occurring at 10
[30] and 12 [25] weeks old. Previous studies suggest there is minimal plaque development by
12 weeks of age [43]. Study duration ranged from 4 weeks [32] to 26 weeks [31], and flavonoid
doses ranged from 0.6mg/kg/d [25] to 100mg/kg/d [33, 38, 39]. Quality assessment revealed
only two studies justified the dosage of flavonoid used [31, 33]. Heterogeneity in study meth-
odology makes quantitative comparisons difficult for individual flavonoids and flavonoid clas-
ses. Future studies would benefit from a stronger rationale for flavonoid dose, mouse age and
study duration, which are poorly justified in many current studies.
Fig 3. Forest plot showing the effects of flavonoids on atherosclerosis lesion area. Sub-analyses were
performed to test the effect of flavonols, flavan-3-ols, isoflavones and flavone glycosides on
atherosclerosis lesion area. The meta-analysis included 11 studies and a total of 18 flavonoid comparisons.
Comparisons were made using standard mean differences and a random effects model. SD, standard deviation;
CI, confidence interval; Std, standard; EMIQ, enzymatically modified isoquercitrin; S, Aortic Sinus; T, Thoracic
Aorta.
https://doi.org/10.1371/journal.pone.0181832.g003
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All studies failed to report reproducibility testing for lesion area measurement, and only
one study reported blinding of the outcome assessor [30]. Furthermore, only one study pro-
vided sample size calculations [31]. Multiple studies did not report body weight or food con-
sumption to allow for accurate conversion to per kilogram dosage. The funnel plot suggested
the possibility of publication bias which may suggest that a number of negative studies have
not been published.
Flavonoids have previously been proposed to influence atherosclerosis development
through multiple mechanisms including improved lipid profile, reduction in LDL-oxidation,
and reductions in a number of inflammatory cells and mediators [44]. At the doses used in the
included studies, purified flavonoids were reported to have no significant effect on plasma TC,
TG, LDL-C or HDL-C in ApoE-/- mice. However, flavonoids were reported to have a signifi-
cant effect on the oxidative stress parameters measured in all individual studies, with the
exception of one study which reported that quercetin, but not catechin, reduced LDL-oxida-
tion ex vivo [30]. Heterogeneity of methods prevented quantitative comparison of the effects
of flavonoids on oxidative stress, however. Direct in-vitro antioxidant effects have been shown
for multiple flavonoids [45], however there is also evidence for an indirect antioxidant effect
through upregulation of endogenous heme oxygenase-1 [35, 46]. Despite the integral role of
LDL-oxidation in the pathogenesis of atherosclerosis, only one of the nine included studies
have measured the effects of a flavonoid on LDL-oxidation in vivo [37].
In addition to antioxidant effects, flavonoids have been reported to reduce endothelial cell
apoptosis, increase aortic endothelial nitric oxide synthase activity [31, 37] and decrease den-
dritic cell number [38]. Flavonoids have also been reported to increase the collagen content of
plaque lesions [26], and decrease expression of CD44 [32], suggesting an ability to promote
atherosclerosis plaque stability [47].
The major classes of flavonoids which have been studied for their anti-atherosclerosis
effects are the flavonols and the flavan-3-ols. Both of these flavonoid classes contain hydroxyl
groups on carbon three of the heterocyclic ring, and are differentiated by whether or not they
contain a ketone functional group on carbon 4 (Fig 1). Flavonoid glycosides were classed as
flavonols due to evidence of metabolism to flavonols within the body [15, 16]. The flavonols
were the most studied flavonoid, included in seven of the nine studies, while flavan-3-ols were
included in two, and isoflavanes and flavone glycosides were included in only one study each.
In sub-analyses limited to the flavonoid class, flavonols but not flavan-3-ols significantly
reduced atherosclerosis lesion area. The small sample size of the flavan-3-ol analysis (57 exper-
imental mice compared with 113 in the flavonol group) may possibly explain this finding.
This finding may also be related to key structural differences between the flavonols and flavan-
3-ols, such as the presence of a ketone functional group in the flavonols but not the flavan-
3-ols. The latter may be important in reducing LDL-oxidation, which was shown to occur after
administering all the flavonols tested [25, 30, 37] but not the flavan-3-ol catechin [30].
Reported beneficial effects of flavonoids on atherosclerosis severity and plaque stability
suggest they may be useful for prevention and treatment of atherosclerosis in humans. A ran-
domized crossover trial reported that quercetin, administered as quercetin-3-glycoside, signifi-
cantly decreased the inflammatory biomarkers soluble endothelial selectin and interleukin 1
beta compared with placebo after four weeks supplementation [48]. However, no other clinical
trials have assessed the effects of quercetin and other flavonoids on markers of atherosclerosis
in humans. The antioxidant effects of the flavonoids are likely to have more impact on the for-
mation of atherosclerosis as opposed to a decrease in size of pre-existing plaques [49]. Modifi-
cations of markers of plaque stability may therefore be a better indication of clinically relevant
benefits of flavonoids in terms of likelihood of reducing cardiovascular events [50]. Currently,
there is some animal research (as discussed above) but no clinical research to support a role of
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flavonoids in increasing plaque stability [26, 32]. Future animal studies should aim to measure
the effects of flavonoids on markers of stability in pre-existing plaque lesions in order to better
evaluate possible clinical outcomes.
Quercetin is currently the most studied flavonoid in animal and human studies. In the
included studies, the highest dose of quercetin administered was 100mg/kg/d [33]. Previous
clinical studies have administered quercetin orally at 15mg/kg/d, for up to eight weeks, without
observable side effects [51]. Based on body surface area calculations, this dose translates to
185mg/kg/d in mice [52]. Therefore the doses used in these preclinical models, which were
found to have beneficial effects on lesion area and atherosclerosis biomarkers, are the equiva-
lent of relatively low doses in humans. Furthermore, quercetin is inexpensive and readily
available as a dietary supplement. Based on the preclinical findings, dose tolerance, cost and
availability of quercetin, future clinical studies should aim to test the benefit of quercetin sup-
plementation in combination with currently used therapies on cardiovascular end points.
The current meta-analysis is limited by a number of factors. Firstly, none of the specific fla-
vonoids have been tested for their effects on lesion area in more than three separate studies.
Therefore we performed a statistical comparison between the most commonly studied flavo-
noid classes, the flavonols and flavan-3-ols, but were unable to compare individual flavonoids.
Secondly, only one of the included studies measured plaque stability, and only one measured
LDL oxidation in vivo, both of which are important in atherosclerosis pathology. Future ani-
mal studies should aim to assess the effects of flavonols on plaque collagen content, as prelimi-
nary evidence suggests they may improve plaque stability, which is a clinically relevant finding.
In conclusion, this meta-analysis suggests that flavonoids reduced the severity of atheroscle-
rosis in ApoE-/- mice. The flavonoid subclass, the flavonols, appear to be the most effective at
reducing lesion area based on the studies available.
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